Vyant Bio (NASDAQ:VYNT) Trading 2.4% Higher

Vyant Bio, Inc. (NASDAQ:VYNT – Get Rating)’s share price traded up 2.4% during trading on Tuesday . The stock traded as high as $0.87 and last traded at $0.85. 29,691 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,575,799 shares. The stock had previously closed at $0.83.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets dropped their price target on shares of Vyant Bio to $5.00 in a research note on Friday, December 2nd.

Vyant Bio Price Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 1.81 and a quick ratio of 1.80. The business has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $2.47.

Vyant Bio (NASDAQ:VYNT – Get Rating) last released its earnings results on Tuesday, November 15th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.48). Vyant Bio had a negative net margin of 4,416.02% and a negative return on equity of 77.68%. The business had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.04 million. On average, analysts predict that Vyant Bio, Inc. will post -2.73 earnings per share for the current year.

Institutional Investors Weigh In On Vyant Bio

An institutional investor recently raised its position in Vyant Bio stock. US Bancorp DE grew its position in Vyant Bio, Inc. (NASDAQ:VYNT – Get Rating) by 3,001.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,813 shares of the company’s stock after buying an additional 24,013 shares during the quarter. US Bancorp DE owned 0.08% of Vyant Bio worth $35,000 at the end of the most recent quarter. 28.74% of the stock is owned by institutional investors and hedge funds.

Vyant Bio Company Profile

(Get Rating)

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.